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Abstract: Hospital-based adverse drug reaction (ADR) monitoring and reporting programs intend
to identify and quantify the risks associated with the use of medicines. To examine the causality,
preventability and severity of ADR in a hospital setting; a prospective cohort study on spontaneous
ADR reporting was conducted from December 2015 to May 2016. Incidence of ADRs, causality, type,
severity and preventability were assessed using necessary assessment scales. The study included
3157 hospitalized individuals, in whom 51 ADRs were detected among 49 patients. The overall
incidence of suspected ADRs was found to be 1.6%. According to the causality assessment, most of
the ADRs reported were probable (n = 26, 51.0%), and type A (augmented/pharmacological) reactions
(n = 39, 76%) were the most common type of ADR found. The majority of ADRs were moderate
to severe (n = 35, 68.6%), of which 37.3% were found to be potentially preventable. Predictability
was observed in 28 (54.9%) reported ADRs. The prescribed medicines most frequently associated
with ADRs were antibiotics, antiepileptics and antihypertensives. This feasibility study was able to
highlight the clinical pharmacist’s role in ADR monitoring service and create awareness about the
way it could be done to promote safer medication use. Similar ADR reporting programs are necessary
to educate and to improve awareness among healthcare professionals in some countries.
Keywords: adverse drug reactions; spontaneous reporting; causality; ADR; severity
1. Introduction
Medications are being widely prescribed for various medical conditions, and the selection of a
medicine is often based on the benefit-risk ratio. Adverse drug reactions (ADRs) are considered one of
the leading causes of morbidity and mortality [1,2]. It is postulated that 5–8% of all hospitalized
individuals experience serious ADRs and 10% of the hospital costs are related to ADRs [3–5].
Hospitalization and complications during hospitalization, such as prolonged hospital stay and
increased healthcare costs, are the burdens mainly associated with ADRs [6,7]. According to the
World Health Organization (WHO) [8], “ADR is a noxious and unintended response that occurs at
doses normally used in humans for prophylaxis, diagnosis or therapy of disease, or for the modification
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of physiological function”. This definition eliminates therapeutic failure, overdose, medication abuse,
noncompliance, and medication error [9,10]. Numerous factors influence ADR susceptibility, including
polypharmacy, age, disease severity and the type of medicines prescribed [11].
ADRs are considered an unnecessary cause to an already burdened healthcare system and
are usually preventable. Although many of the regulatory agencies obligate ADR monitoring, it
is not extensively accomplished in Indian hospitals. In some countries, ADRs are under-reported
and undisclosed due to lack of drug monitoring and prioritization of medication safety [12]. The
extent of medication use differs across countries, and the findings from each population cannot be
generalized [13,14]. Since the number of medications and their usage have increased recently, the
early detection of ADRs is essential to monitor both known and unknown effects of a medication [15].
A recent systematic review reported that the median incidence rate of ADRs among Indian hospitals is
high (12.9%) [11].
Hospital-based ADR reporting programs can provide valuable information about the potential
issues associated with medication usage in that institution. In addition, the ability to detect rare ADRs
and to generate new signals would enhance a sound pharmacovigilance system in the country by
revealing unusual or rare ADRs to the Indian population. However, physicians are still unaware
of ADR reporting and monitoring services, as many untoward adverse incidents are unrecognized
in an Indian hospital setting [16]. Conducting prospective studies allows more precise reporting of
medication-related history and symptoms to assess the causality of ADRs. Hence, the aim of this study
was to examine the ADRs in a tertiary care hospital and assess the type, causality, preventability and
severity of the ADRs. The present study was intended to monitor ADRs in a tertiary care hospital
where the clinical pharmacy services has been already established.
2. Methods
This prospective cohort study was conducted in the inpatient medical wards at PVS Hospital
(P) LTD, Calicut, Kerala, India, a 350-bed tertiary care teaching hospital. The study duration was six
months, from December 2015 to May 2016. A prospective spontaneous ADR reporting method was
followed for the study. Since 1960, WHO is using spontaneous reporting systems, also called ‘early
warning’ systems [17] which is widely recognized in many countries.
Awareness about the ADR monitoring and reporting was given to the physicians, surgeons,
nurses, pharmacists and allied medical staff of the hospital. Routine case-sheet review and medication
order review were done by the clinical pharmacists. For each patient, the prescribed medications
were noted and possible occurring ADRs were listed from relevant references. Each day, the patients
were interviewed and checked for the identified ADRs and reported the classification, causality,
preventability and severity using appropriate measures. The ADR report of the concerned patient
was submitted to the physician or surgeon in-charge in the form of ‘thank you note’ (Supplementary
Table S1). The ADR reports were finally documented in the ADR documentation forms (Supplementary
Table S2). ADR notification forms were given to all the inpatient units, and these helped with reporting
of ADRs at times when the clinical pharmacists were not available during the occurrence of an ADR
(Supplementary Table S3).
The reported ADRs on the notification forms, after been confirmed by the physician-in-charge,
were assessed for causality using Naranjo’s algorithm scale [18], type of ADR using Wills and Brown
classification [9], preventability using Modified Schumock and Thornton scale [19] and severity
using Modified Hartwig and Siegel scale [20]. Predictability was assessed based on the incidence
rate of the reported ADRs as per product information and relevant literatures. The completed ADR
documentation was countersigned by the physician-in-charge. We led individual causality assessments
to improve the accuracy of ADRs.
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2.1. Statistical Analysis
All descriptive statistical analysis will be performed using SPSS version 24 (IBM Corp., Armonk,
NY, USA). Rate of ADR occurrence and total number of inpatients during the study period was
compared to identify the overall incidence of ADRs. The Chi-square test was used to analyze
categorical data.
2.2. Ethical Approval
The institutional ethics committee of PVS Hospital (P) Ltd., Calicut, Kerala, India approved
clearance for this study.
3. Results
The study recorded 3157 inpatient admissions during the study period, of which 51 ADRs were
detected among 49 patients. The overall ADR incidence rate was 1.6%. Females experienced a higher
incidence of ADRs (1.6%) than males (1.5%). The male to female ratio according to occurrence of ADRs
was 0.8. Adult (19–64 years) patients experienced a higher number of ADRs (n = 23, 46.9%) than older
people (n = 21, 42.9%) aged 65 and above. The least number of ADRs were found in young patients
(n = 5, 10.2%) aged 18 years or younger. A summary of patient characteristics is given in Table 1.
Table 1. Characteristics of the study population (n = 3157).
Demographic Characteristics Number of Patients with ADR Percentage (%)
Sex *
Male 21 42.9
Female 28 57.1
Age (years) *
≤18 5 10.2
19–64 23 46.9
≥ 65 21 42.9
ADR per patient At least one 48 98.0
Greater than one 1 2.0
* Chi square test shows not significant at p < 0.05.
Particulars on the classification and other assessments of ADRs are given in Table 2. In relation to
the Wills and Brown classification, 39 (76.5%) ADRs were type A (augmented) reactions and 10 (19.6%)
were type H (hypersensitivity) reactions. According to the Naranjo’s algorithm scale, 26 (51.0%)
reactions had probable relation to the suspected medications and 25 (49.0%) had possible relation to
the suspected medications. The overall severity assessments showed that the majority of the reactions
reported were moderate (35, 68.6%), followed by mild (11, 21.6%) and severe (5, 9.8%) reactions.
Assessment on preventability showed that 19 (37.3%) ADRs were probably preventable, 17 (33.3%)
were not preventable and 15 (29.4%) were definitely preventable. The study observation showed that
28 (54.9%) of ADRs were predictable and rest of the 23 (45.1%) were unpredictable.
Among 15 (29.4%) patients, the suspected medication was stopped and substituted with another
medication for the same indication. In addition, another medication was added to relieve the ADR in
9 (17.7%) patients, and the dose of suspected medication was reduced to ameliorate the symptoms
in 12 (23.5%) patients. Among the observed ADRs, 29.4% of the suspected drugs were discontinued,
followed by another 29.4% of medications being withdrawn, and an additional treatment/antidote
given to manage ADRs. The outcome of ADR management showed 58.8% were recovered and 41.2%
were in the process of recovering phase. The most common medications causing ADRs and their
reactions are given in Table 3. Antibiotics were associated with most number of the ADRs reported
(n = 14, 27.5%), with ciprofloxacin (n = 2, 3.9%) and metronidazole (n = 2, 3.9%) associated with the
highest number of ADRs.
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Table 2. Summary of adverse drug reactions based on severity, preventability, predictability,
management and outcome.
Parameter Frequency (n = 51)
Classification (Wills and Brown Classification)
Type A-Augmented 39 (76.5%)
Type B-Bugs 0
Type C-Chemical 1 (2.0%)
Type D-Delivery 1 (2.0%)
Type E-Exit 0
Type F-Familial 0
Type G-Genotoxicity 0
Type H-Hypersensitivity 10 (19.6%)
Type U-Unclassified 0
Causality (Naranjo’s algorithm scale)
Probable 26 (51.0%)
Possible 25 (49.0%)
Definite 0
Unlikely 0
Severity (Modified Hartwig and Siegel scale)
Mild-Level 1 0
Mild-Level 2 11 (21.6%)
Moderate-Level 3 25 (49.0%)
Moderate-Level 4 (a) 8 (15.7%)
Moderate-Level 4 (b) 2 (3.9%)
Severe-Level 5 5 (9.8%)
Severe-Level 6 0
Severe-Level 7 0
Preventability (Modified Schumock and Thornton scale)
Definitely preventable 15 (29.4%)
Probably preventable 19 (37.3%)
Not preventable 17 (33.3%)
Predictability (based on the incidence rate of the reported ADRs as per product information and
relevant literatures)
Predictable 28 (54.9%)
Unpredictable 23 (45.1%)
Management
Stopped the medication 15 (29.4%)
Substituted another drug 15 (29.4%)
Reduced the dose 12 (23.5%)
Added another drug 9 (17.7%)
Outcome of management
Recovered 30 (58.8%)
Recovering 21 (41.2%)
Fatal 0
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Table 3. Drug classes commonly associated with adverse drug reactions.
Drug Class (n, %) Medication Reaction Details
Antibiotic (14, 27.5)
Ciprofloxacin Redness and itching
Metronidazole Vomiting, Thrombophlebitis
Ofloxacin Seizure
Amoxicillin + Clavulanic acid Fever
Cefoperazone + Sulbactam Inflammation of vein, Diarrhea
Rifampicin + Isoniazid +
Pyrazinamide + Ethambutol Nausea
Amoxicillin Colitis
Cefotaxime Itching and rash
Ceftazidime + Tobramycin Itching and rash
Ceftriaxone Thrombocytosis
Antiepileptic (11, 21.6)
Sodium valproate Alopecia
Carbamazepine Fatigue, Blurred vision, Ataxia
Clobazam Memory loss, Hypersomnia
Topiramate Anorexia
Levetiracetam Decreased appetite
Oxcarbamazepine Hypersomnia and fatigue
Antihypertensive (4, 7.8)
Bisoprolol, Carvedilol Increased breathlessness and QTprolongation
Furosemide Hyponatremia, Hypokalemia
Telmisartan, Cilnidipine Hypotension
NSAID (3, 5.9)
Ketorolac Periorbital edema, Redness and itching
Mefenamic acid Gastritis
Antipsychotics (2, 3.9) Olanzapine + Quetiapine Extra pyramidal symptoms
Quetiapine Fatigue
Statin (2, 3.9)
Atorvastatin Myopathy
Rosuvastatin Myopathy
Antifungal (2, 3.9) Amphotericin B Renal failure, Diarrhea
Anesthetic (3, 5.9) Bupivacaine Post spinal headache *
Cognition enhancer (1, 2.0) Cerebroprotein hydrolysate Itching
Antidiabetic (1, 2.0) Glimepiride Hypoglycemia
Anti-craving agent (1, 2.0) Acamprosate Diarrhea
Antiplatelet (1, 2.0) Clopidogrel Abdominal pain
Diagnostic agent (1, 2.0) Iopromide Anaphylactic shock
Antianginal (1, 2.0) Isosorbide dinitrate Hypotension
Antineoplastic (1, 2.0) Rituximab Shivering and breathing difficulty
Others (3, 5.9)
Prazosin Generalized maculopapular rashes
Paracetamol Nephropathy
Insulin, Furosemide Hypokalemia
NSAID = Nonsteroidal anti-inflammatory drugs; * = more than once.
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4. Discussion
This study examined and explored the types of ADRs and their causality, preventability and
severity among hospitalized individuals. The evidence from the current study found an overall
incidence rate of ADR to be 1.6%, where females showed a higher incidence rate of ADR than males.
However, a meta-analysis conducted by Lazarou et al. [4] found a 15.1% incidence rate of ADR among
the hospitalized patients. One of the main reasons for a lower incidence rate in our study is that we
followed spontaneous reporting system while Lazarou et al. [4] identified ADRs using the prospective
surveillance method. Some major flaws of spontaneous reporting system are incompleteness of data
collection in terms of quality and quantity, underreporting, lack of established risk factors, reporting
bias, and death due to an ADR may be recorded incomplete [21]. A review of observational studies in
Europe reported a lower incidence rate of ADR (3.6%) amid all hospitalizations (median; mean 4.6%)
in 22 studies among unselected patient populations [22]. A study conducted from Nepal also reported
a lower prevalence of ADR (0.86%) [23].
One of the limitations of this study was the use of spontaneous reporting system that leads
to lower rates of ADR reporting. According to the literature, under-reporting is one of the major
limitations of spontaneous reporting system followed by variable quality of the reported data and
sparse information on medication exposure [21,24–26]. Use of Naranjo scale was identified as another
limitation of this study. Recent studies have questioned the use of Naranjo’s algorithm and compared
new instruments against the superseded Naranjo scale. Adapted from the Naranjo algorithm, recently
a new assessment method was developed known as the Liverpool ADR Causality Assessment Tool
(LCAT) showed high interrater agreement when used by its developers [27,28].
Our study’s findings show that older patients experience higher incidence of ADRs (2.2%) when
compared to the adult patients (1.5%) and younger patients (0.7%). Likewise, numerous studies
have found an up to two-fold increase in the number of older people being hospitalized because of
ADR-related problems compared to their younger counterparts [29–31].
Results from our study illustrate that antibiotics (27.5%) were the most commonly involved
medication classes associated with ADRs, followed by antiepileptic medicines (21.6%). This could be
due to the wide usage of antibiotics at our study site and based on the number of medications, the
chances are high for developing an ADR. Studies report that antibiotics led to 19.0% of emergency
department admissions for suspected ADRs in the US between 2004 and 2006 [32]. Another recent
study reported that antibiotics (20.8%) are the second most common medication classes associated
with ADRs [33].
Wills and Brown classification of ADR reveals that type A (augmented) reactions (76.5%) were
most commonly reported, followed by type H (hypersensitivity) reactions (19.6%), which is consistent
with literature [34]. Naranjo’s causality algorithm found that most of the reactions had probable
relation to the suspected medications (51.0%) followed by possible relation (49.0%), though various
measures mentioned in Naranjo’s algorithm were not practically possible at the study site, such as
placebo response and drug concentration estimation in body, and these findings would have made a
difference in the assessment of causality. Overall, the severity assessment of ADRs using Modified
Hartwig and Siegel scale found that most of the ADRs belonged to the moderate (68.6%), followed by
mild (21.6%) and severe (9.8%) category. Similar findings were reported by Emma and colleagues from
the United Kingdom among 3695 hospitalized inpatients [6].
An Australian study reported that more than 50% of ADR-related hospital admissions were
preventable [35]. Similarly, in our study, preventability assessment using Modified Schumock and
Thornton scale shows 37.3% of ADRs were probably preventable, while 33.3% were not-preventable
and 29.4% were definitely preventable. In addition, our study found that most of the ADRs were
predictable (54.9%) and would have been monitored closely to prevent an adverse effect.
Remarkably, our study captured a wide array of ADRs associated with inpatient medication use,
and this generated signal would facilitate the healthcare professionals to be vigilant and cautious in
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prescribing and administering medications to inpatients. The medications that are most frequently
associated with ADRs were antibiotics, antiepileptics, antihypertensives and pain medications (Table 3).
In India, epidemiological data concerning ADRs are limited to the incidence, risk factors, outcome
and other clinical characteristics. Most Indian studies are based on a single center, small sample and
limited duration; hence, they lack representativeness, and it is difficult to extrapolate data from these
studies to nationwide. This was one of the limitations of our study. Our study found that by conducting
varied ADR assessment scales, we can create awareness about the importance of ADR reporting and
thereby promote safer medication use. Similar reporting programs are necessary to educate and to
increase awareness about reporting ADRs among the healthcare professionals in some countries.
With the drive to prevent ADRs, interventions that are successful in other countries should
be applied in Indian hospital settings, such as implementation of clinical decision support system,
computerized medication entry and digital medical record system [36], engagement of full time clinical
pharmacists as part of the medical team [37,38] and enabling medication reconciliation during the
hospital admission [39]. Numerous ADR risk prediction tools are available and have been published;
however, none are globally accepted and are cast off routinely in clinical practice. In future, a sound,
widely accepted and validated ADR risk prediction tool is warranted to minimize the risk of ADRs.
Newer studies and instruments are warranted to detect preventable ADRs similar to the ‘P Method’
(preventability assessment method) [40]. To further evaluate medication-event causality, MOdified
NARanjo Causality Scale for individual case safety reports (MONARCSi) was developed to support
pharmacovigilance [41].
5. Conclusions
The pattern of ADRs reported by the clinical pharmacy department was comparable with the
results from studies conducted elsewhere in a hospital setting. The study was able to showcase
the role of clinical pharmacist in monitoring the ongoing safety of medicines through continuous
ADR reporting. The findings will encourage the healthcare team to be aware of more ADR-prone
medications and their preventability by enhancing the aptitude of prescribers to manage ADRs more
effectively. Over half of the reported ADRs are definitely or probably avoidable, and further actions
should be taken to present strategies to reduce their impact. Standardized ADR risk prediction tools are
useful adjuncts, together with sound clinical judgement underpinned by a trained clinical pharmacist,
to monitor ADRs in a hospital setting.
Supplementary Materials: The following are available online at http://www.mdpi.com/2226-4787/6/4/108/s1,
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